Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search or filter for trials that may be right for you, or learn more about what it means to be a trailblazer.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn more about what it means to be a trailblazer.
Showing 1-7 of 163 studies
-
Restore CFTR FunctionEnrolling
Phase 2 study of PTI-428 drug in people with CF ages 18 and older who have two copies of the F508del CFTR mutation , protocol number Proteostasis PTI-428-06This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug PTI-428 and how it is processed by the body. It is for people with CF ages 18 and older who have two copies of the F508del CFTR mutation and are already taking tezacaftor/ivacaftor.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
74 days
-
-
Mucociliary ClearanceEnrolling
SHIP CT: Study of hypertonic saline in preschoolers , protocol number SHIP002This study is taking place in Europe, Australia and the U.S. It will look at the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in children with CF.
-
Age:
3 Years to 5 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
6
-
Length of Participation:
54 weeks
-
-
Anti-InflammatoryEnrolling
Phase 2 study of lenabasum in people with CF ages 12 and older , protocol number Corbus JBT101-CF-002This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the potential anti-inflammatory drug lenabasum and will use a placebo control.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Anti-InfectiveEnrolling
Phase 2 study of inhaled nitric oxide in people with CF , protocol number Novoteris NO-CF-02EThis study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug nitric oxide in adults with cystic fibrosis who are taking an inhaled antibiotic.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
35 to 85%
-
Number of Visits:
10
-
Length of Participation:
43 days
-
-
Nutritional-GIEnrolling
OPTION: Study of AzurRx MS1819 in people with cystic fibrosis and exocrine pancreatic insufficiency who are 18 years and older , protocol number AzurRX AZ-CF2001This study will look at the safety and effectiveness of the drug MS1819 as a pancreatic enzyme replacement therapy.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
30% or greater
-
Number of Visits:
10
-
Length of Participation:
11 weeks
-
-
ObservationalEnrolling
Rare mutation cell collection (RARE) , protocol number RARE-OB-16This study is taking place at multiple care centers across the U.S. Researchers will collect and make available for study cells from people with rare CFTR mutations.
-
Age:
2 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
1
-
Length of Participation:
1 days
-
-
OtherEnrolling
Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
49 days
-
Showing 1-7 of 163 studies
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Clinical Studies 101
-
Questions to Ask When Considering a Specific Trial
Clinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.
-
Patient Safety Is a Priority
Nothing is more important than patient safety in developing new treatments for cystic fibrosis. The U.S. government requires that all clinical trials are supervised for safety, and the Cystic Fibrosis Foundation adds additional measures to protect study volunteers.
-
How Do Clinical Trials Work
Each clinical trial has a study sponsor and a protocol. Potential drugs must move through four well-defined phases of testing in patients.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More